Original articles: Asthma, rhinitis, other respiratory diseasesMometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma☆
Section snippets
Methods
This randomized, placebo-controlled, single-center, 3-phase cross-over, double-blind study was designed to evaluate the effect of 2 low doses of MF DPI on AMP-induced bronchoconstriction compared with placebo in patients previously maintained on inhaled β-agonists alone.
Demographics
This study included 7 female and 8 male patients between the ages of 21 and 49 years. All patients were white. There was a wide variation in patient PC20 before treatment. At the beginning of phase I, before the administration of any study medication, PC20 values ranged from 1.02 mg/mL to 79.37 mg/mL with a median of 3.15 mg/mL.
One patient discontinued the study during the first treatment phase and one during the second treatment phase (see Safety). Thirteen patients completed all 3 treatment
Discussion
Treatment with MF DPI at 2 low doses (50 and 100 μg BID) for 2 weeks successfully antagonized AMP-induced bronchoconstriction. The PC20 (expressed as doubling dilutions) increased by approximately 3-fold relative to placebo for both doses of MF DPI. Treatment with both doses also resulted in improvement in pulmonary function, patient-reported symptoms, and investigator assessments of response to therapy.
Airway inflammation is a major factor contributing to disease severity and bronchial
References (22)
- et al.
Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis
Ann Allergy Asthma Immunol
(1997) - et al.
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler
Respir Med
(1999) - et al.
The inhibitory effects of topically active glucocorticoids on IL-4, IL- 5, and interferon-gamma production by cultured primary CD4+ T cells
J Allergy Clin Immunol
(1997) - et al.
Glucocorticoids inhibit proliferation and interleukin-4 and interleukin- 5 secretion by aeroallergen-specific T-helper type 2 cell lines
Ann Allergy Asthma Immunol
(1998) - et al.
Relative potencies and time course of changes in adenosine 5′- monophosphate airway responsiveness with inhaled furosemide and bumetanide in asthma
J Allergy Clin Immunol
(1993) - et al.
A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial
J Allergy Clin Immunol
(1992) - et al.
Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis
Otolaryngol Head Neck Surg
(1998) Inflammation in asthma: the cornerstone of the disease and target of therapy
J Allergy Clin Immunol
(1998)- et al.
A comparison of the efficacy and safety of inhaled corticosteroids in asthma
Allergy
(1997) - et al.
Efficacy and safety of inhaled cortico-steroids: new developments
Am J Respir Crit Care Med
(1998)
Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent
Cutis
Cited by (32)
Effects of low- versus high-dose fluticasone propionate/formoterol fumarate combination therapy on AMP challenge in asthmatic patients: A double-blind, randomised clinical trial
2016, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :All treatments were administered via the AeroChamber Plus® spacer device. The doses of fluticasone/formoterol were selected as a pairwise dose-response was considered unlikely to be seen without a four- to five-fold ICS dose difference [20,27–30]. FeNO was measured with a NIOX-MINO™ analyser (Aerocrine, Solna, Sweden) per current guidelines [31].
Rapid effect of inhaled ciclesonide in asthma: A randomized, placebo-controlled study
2008, ChestCitation Excerpt :The improvements in AHR to AMP and exhaled NO levels were of similar magnitude to those reported in the present study. Furthermore, the effects of ciclesonide are consistent with those of other ICS in patients with mild asthma, with PC20FEV1 improved by approximately two to three doubling doses.16,20,21 Budesonide has been shown to significantly improve AHR and decrease sputum eosinophils after 6 h of treatment,22,23 and reduce exhaled NO levels after 3 days of treatment.16,24
Mometasone furoate administered by Twisthaler™, a new inhaled corticosteroid
2004, Revue Francaise d'Allergologie et d'Immunologie CliniqueResearch applications and implications of adenosine in diseased airways
2003, Trends in Pharmacological SciencesRapid effect of inhaled fluticasone on airway responsiveness to AMP: Research implications [8] (multiple letters)
2003, Journal of Allergy and Clinical ImmunologyDose response of inhaled corticosteroids on bronchial hyperresponsiveness: A meta-analysis
2003, Annals of Allergy, Asthma and Immunology
- ☆
Reprint requests: Stephen T. Holgate, MD, DSc, Southampton General Hospital, Southampton University, Med I, Level D, Southampton, S016 6YD United Kingdom.